This week, the ratings of three Pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, VIVUS Inc. (NASDAQ:VVUS) falls to a D (“sell”), worse than last week’s grade of C (“hold”). VIVUS is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. In Portfolio Grader’s specific subcategory of Equity, VVUS also gets an F. As of May 10, 2013, 26.2% of outstanding VIVUS Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VVUS stock.

This week, Cempra Holdings LLC’s (NASDAQ:CEMP) rating worsens to a D from the company’s C rating a week ago. Cempra manufactures and markets pharmaceutical products. The stock gets F’s in Equity and Cash Flow.

For a full analysis of CEMP stock, visit Portfolio Grader.

Corcept Therapeutics’ (NASDAQ:CORT) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Corcept Therapeutics engages in the discovery, development, and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. The stock gets F’s in Equity and Cash Flow. The stock price has fallen 6.6% over the past month, worse than the 3.3% increase the Nasdaq has seen over the same period of time. To get an in-depth look at CORT, get Portfolio Grader’s complete analysis of CORT stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.